Clinical trials: Diffuse Parenchymal Lung Diseases
NSCLC, Nintedanib
Nintedanib for the Prevention of Radiation Pneumonia in Unresectable NSCLC
This study is aimed at patients with unresectable NSCLC who take nintedanib during sequential radiotherapy to explore the incidence of radiation pneumonitis above grade 2 in the nintedanib combined with radiotherapy mode and…
- Conditions
- NSCLC, Nintedanib, Radiation Pneumonitis
- Trial name
- NCT06570317
- Testing
- Nintedanib
- Where
- 7 sites in China
- Volunteers
- 40 people
- Sponsor
- Second Hospital of Shanxi Medical University
SARS-CoV-2 Infection, Lung Fibrosis
Study to Assess Efficacy and Safety of Treamid for Patients With Reduced Exercise Tolerance After COVID-19
The innovative drug Treamid is planned for use in the treatment of patients with persistent lung damage and reduced exercise tolerance exertion after COVID-19 pneumonia in a multicenter, randomized, double-blind…
- Trial name
- NCT05516550
- Testing
- Treamid, Treamid twice a day, Treamid once a day
- Volunteers
- 412 people
- Sponsor
- PHARMENTERPRISES LLC
Interstitial Lung Disease Due to Systemic Disease (Disorder), Interstitial Lung Disease in Patients With Rheumatoid Arthritis
Teleconsultation Approach to CTD-ILD Care Delivery in Rural UnderServed CommuniTies (TRUST Initiative)
Connective tissue disease-associated interstitial lung disease (CTD-ILD) is a rare and complex condition that affects some individuals with autoimmune disorders such as rheumatoid arthritis (RA).
- Conditions
- Interstitial Lung Disease Due to Systemic Disease (Disorder), Interstitial Lung Disease in Patients With Rheumatoid Arthritis, Interstitial Lung Disease Due to Systemic Disease
- Trial name
- NCT07217093
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- St. Lawrence Health System
Sars-CoV-2 Infection, Lung Fibrosis
Low-field Magnetic Resonance Imaging of Pediatric COVID-19
SARS-CoV-2 (Severe acute respiratory syndrome coronavirus type 2) is a new coronavirus and identified causative agent of COVID-19 disease. They predominantly cause mild colds but can sometimes cause severe pneumonia.
- Conditions
- Sars-CoV-2 Infection, Lung Fibrosis, Covid19
- Trial name
- DECRYPT (NCT04990531)
- Testing
- Low-field magnetic resonance imaging, Blood sample
- Where
- Germany
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- University of Erlangen-Nürnberg Medical School
Idiopathic Pulmonary Fibrosis
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
This Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 (NCT00391443) will asses the long term safety and tolerability of bosentan in patients with idiopathic…
- Trial name
- BUILD OL (NCT00631475)
- Testing
- Bosentan
- Volunteers
- 128 people
- Sponsor
- Actelion
Idiopathic Pulmonary Fibrosis
Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF)
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive form of lung disease characterized by fibrosis of the supporting framework (interstitium) of the lungs.
- Trial name
- NCT01504334
- Testing
- Pirfenidone
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Beijing Kawin Technology Share-Holding Co., Ltd.
Interstitial Lung Diseases
Interstitial Lung Diseases in Respiratory ICU
This is Prospective observational study to analyze the clinical features, risk factors, outcome,mortality rates in interstitial lung diseases patients who required admission in Respiratory ICU
- Trial name
- NCT07117253
- Volunteers
- 50 people
- Sponsor
- Sohag University
Idiopathic Pulmonary Fibrosis
Pennsylvania Idiopathic Pulmonary Fibrosis Research Registry
The Pennsylvania Idiopathic Pulmonary Fibrosis State-wide Research Registry (PA-IPF) is a cooperative project between five medical centers to coordinate a team of investigators.
- Trial name
- PA-IPF (NCT00540475)
- Where
- 5 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- University of Pittsburgh
Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis
Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis
This study will explore how adults in Japan with pulmonary fibrosis decide whether to continue or discontinue antifibrotic therapy after experiencing antifibrotic therapy-related adverse events.
- Conditions
- Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
- Trial name
- UPWARD (NCT07722507)
- Testing
- Antifibrotic therapy
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Bristol-Myers Squibb
Antisynthetase Syndrome, Tocilizumab
Tocilizumab in Refractory ASS-ILD
Refractory anti-synthetase syndrome-associated interstitial lung disease (ASyS-ILD) lacks targeted therapy. Interleukin-6 drives both inflammation and fibrosis.
- Trial name
- NCT07662265
- Testing
- Tociliuzumab
- Where
- China
- Volunteers
- 111 people
- Sponsor
- Hu Yinan
Antisynthetase Syndrome (ASS), Interstitial Lung Disease
Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease
"Antisynthetase syndrome (ASS) is one of the most severe inflammatory myopathy (IM), due to pulmonary involvement (interstitial lung disease, ILD).
- Trial name
- CATR-PAT (NCT03770663)
- Testing
- Cyclophosphamide and azathioprine, Tacrolimus
- Where
- France
- Volunteers
- 76 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary Fibrosis
The primary objective of this study is to establish the feasibility and safety of infusions of placental Mesenchymal Stem Cells (MSC) from related or unrelated HLA identical or HLA mismatched donors in the treatment of Idiopathic…
- Trial name
- MSC in IPF (NCT01385644)
- Testing
- Placental MSC
- Where
- Australia
- Volunteers
- 8 people
- Sponsor
- The Prince Charles Hospital
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis
Granulomatosis with polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA) are two rare immune system disorders that cause the inflammation of blood vessels, or vasculitis.
- Conditions
- Granulomatosis With Polyangiitis, Microscopic Polyangiitis, Wegener's
- Trial name
- NCT00315393
- Where
- 8 sites in United States, Canada
- Volunteers
- 1,046 people
- Sponsor
- University of Pennsylvania
Idiopathic Pulmonary Fibrosis
Comparing Measurements Made in an Incremental Shuttle Walk Test and a Cardiopulmonary Exercise Test in Patients With IPF
Idiopathic pulmonary fibrosis (IPF) is a chronic and potentially fatal lung disease. As IPF progresses, patients become increasingly breathless with reduced exercise capacity and quality of life.
- Trial name
- NCT03360032
- Where
- United Kingdom
- Volunteers
- 43 people
- Sponsor
- University Hospitals Coventry and Warwickshire NHS Trust
Systemic Lupus, Rheumatoid Arthritis
Yellow Fever Vaccine in Patients With Rheumatic Diseases
According to World Health Organization (WHO), since December 2016, Brazil is showing a significant increase in cases of yellow fever in humans.
- Conditions
- Systemic Lupus, Rheumatoid Arthritis, Spondyloarthritis, Inflammatory Myopathy
- Trial name
- NCT03430388
- Testing
- Yellow Fever vaccine (17D)
- Where
- Brazil
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Idiopathic Pulmonary Fibrosis
Yoga Effect on Quality of Life Study Among Patients with Idiopathic Pulmonary Fibrosis
This study will evaluate whether regular yoga exercises designed specifically for patients with Idiopathic Pulmonary Fibrosis is associated with any change in quality of life.
- Trial name
- YES-IPF (NCT02848625)
- Testing
- Yoga
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- University of Washington
Covid19, Post-acute COVID-19 Respiratory Disease
LYT-100 in Post-acute COVID-19 Respiratory Disease
This study is being conducted in two parts, A and B. Part A is a randomized, double-blind, parallel arm study to evaluate the safety and efficacy of LYT-100 compared to placebo in adults with post-acute COVID-19 respiratory…
- Trial name
- NCT04652518
- Testing
- LYT-100
- Where
- 31 sites in United States, Argentina and 6 more
- Volunteers
- 185 people
- Sponsor
- PureTech
Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis
Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients
Pulmonary diseases are increasingly important causes of morbidity and mortality in the modern world. Sildenafil, an orally administered a phosphodiesterase type 5 (PDE-5) inhibitor, targets the nitric oxide (NO) pathway.
- Trial name
- NCT01382368
- Testing
- Sildenafil
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Rabin Medical Center
Interstitial Lung Disease
Study Comparing Two Different Methods of Cryobiopsy in the Interstitial Lung Diseases
Interstitial lung diseases (ILD) are a heterogeneous collection of more than 100 different pulmonary disorders. Surgical lung biopsie in combination with multidisciplinary discussion is recommend in combination to reach a…
- Trial name
- NCT03727568
- Testing
- Cryobiopsy
- Where
- Germany
- Volunteers
- 140 people
- Sponsor
- University Hospital, Essen
Idiopathic Pulmonary Fibrosis, Hypoxemia
Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF
This study is a randomized, double-blind, placebo-controlled trial in which eligible IPF subjects will be randomized to receive GBT440 or Placebo orally daily.
- Trial name
- NCT02846324
- Testing
- GBT440
- Where
- 12 sites in United States
- Volunteers
- 39 people
- Sponsor
- Global Blood Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.